• Spero Therapeutics stock is trading at $1.60 (-5.88%), extending losses from a -22.02% drop on July 14, 2026.
  • The decline follows investor reaction to the company's July 14 announcements of an exclusive licensing agreement for SP001, potentially valued at $1.1 billion, and $105 million in non-recourse royalty financing.
  • The market appears to be reacting negatively to the strategic pivot towards immunology and inflammation and the financial commitments associated with the SP001 deal, despite the new funding.